European Respiratory Journal

Papers
(The TQCC of European Respiratory Journal is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The right ventricle tamed1114
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis846
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?710
Chymase-1: a “MAST”-er switch in COPD?352
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence220
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease210
Missing airways, ventilation defects and conductive airway physiology in asthma187
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe175
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow153
A breath of the future: a novel human model for COPD and beyond146
The lung that rules the heart139
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?134
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?132
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan132
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?125
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?121
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al117
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis117
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial115
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)107
Combining rituximab with mycophenolate for the treatment of interstitial lung disease103
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor102
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis101
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms97
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study96
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD94
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study93
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections91
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea90
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis86
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume85
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target85
Soteria: deliverance from harm?83
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation82
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era82
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet82
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis81
The environmental impact of inhaled therapy: making informed treatment choices81
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey81
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD80
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?78
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD78
Treatment algorithm for pulmonary arterial hypertension78
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?78
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection78
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study76
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis76
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis75
Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension74
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients74
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety73
Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis71
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension71
Reply: Tuberculosis screening in migrants to the EU/EEA and UK64
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?64
The limits of normal of pulmonary arterial wedge pressure64
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough63
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis62
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines62
Pleural mesothelioma: surgery questioned again?61
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?60
The efficacy of singingversusexercise training: do the data really support the authors’ conclusions?59
List ofEuropean Respiratory Journalpeer reviewers 202359
Particulate matter–related ITIH4 deficiency is associated with an emphysema phenotype of chronic obstructive pulmonary disease through JNK-dependent and JNK-independent signaling58
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander,et al.Eur Respir J2023; 62: 2300011.58
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination58
CPAP recall and cancer risk: should we be concerned?58
FEV1Q: what (even) is normal lung function?58
Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study57
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis57
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study57
WHO online guide on the use of digital technologies for tuberculosis programmes55
Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures55
Prognostic phenotypes of early-stage lung adenocarcinoma55
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment51
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain51
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme50
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension50
The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation50
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis49
The association between immunosuppressants and outcomes of COVID-1949
Childhood asthma: pathogenesis and phenotypes48
Theratyping in cystic fibrosis: filling the knowledge gaps48
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations48
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac indexversusstroke volume index47
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients47
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis47
Early-life exposure to mixture of phenols and respiratory health in pre-school children47
Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!45
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain45
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease45
Oxygen therapy target ranges: finding the balance44
Reply to: Cause or consequence?44
Oral corticosteroids in asthma and beyond: moving forward44
Unravelling the unmet needs of patients with severe dyspnoea: a case for palliative oxygen44
Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis43
Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism: results from the REVERSE study43
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease43
Cardiopulmonary response to exercise in adults born very preterm43
ERJPodcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma42
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia42
ERJPodcast January 2024: The microbiome in early life and childhood asthma41
COVID-19 changed the world – without changing CTEPH41
Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?41
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography41
Bronchoconstriction with inhaled ATP in healthy volunteers41
Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants41
Multitasking within the airway epithelium41
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study41
Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999–200240
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)40
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA40
Is tezepelumab more than just an anti-eosinophil drug?40
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system40
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema38
Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis38
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry38
Transcriptomic clustering of critically ill COVID-19 patients38
Indoor microbiome, microbial and plant metabolites, chemical compounds, and asthma symptoms in junior high school students: a multicentre association study in Malaysia38
Metabolomics in pulmonary medicine: extracting the most from your data38
Flavonoid intakes inversely associate with COPD in smokers38
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease37
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism37
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases37
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension37
Air pollution and COPD: GOLD 2023 committee report37
European Respiratory Society guidelines for the diagnosis of asthma in adults37
Moving the dial on identifying endotypes of asthma from early life37
Presenting clinical data for the hazard classification of chemical respiratory sensitisers36
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study36
Aspergillussensitisation: an underappreciated treatable trait in airway disease35
Spirometry forced expiratory time is driven by airflow limitation in asthmatic children35
Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content35
Evolving diagnostic techniques in mediastinal lymphadenopathy: is mediastinal cryobiopsy the new kid on the block?35
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud35
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−134
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–201634
Lung function during and after acute respiratory infection in COVID-19 positive and negative outpatients33
Developing, validating, updating and judging the impact of prognostic models for respiratory diseases33
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!33
Technical standards for respiratory oscillometry and bronchodilator response cut-offs33
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle33
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways32
Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series32
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study32
Relieving dyspnoea through the brain32
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium32
Incidence of interstitial lung abnormalities: the MESA Lung Study32
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis32
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma32
Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy32
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned32
Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus32
Asthma, COPD and their overlap: coexistence or something more?32
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background32
Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis32
Ex vivodelivery of regulatory T-cells for control of alloimmune priming in the donor lung31
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis31
Primary spontaneous pneumothorax: does size matter?31
Lung transplantation for acute respiratory distress syndrome: a retrospective European cohort study31
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study31
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort31
The role of precision medicine in interstitial lung disease31
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care31
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles31
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance31
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement31
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi30
Progressive pulmonary fibrosis: an expert group consensus statement30
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health30
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study30
Pulmonary hypertension associated with left heart disease30
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis30
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse29
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges29
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial29
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial29
Sleep apnoea in the elderly: a great challenge for the future29
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)29
Association of blood trihalomethane concentrations with asthma in US adolescents: nationally representative cross-sectional study29
List ofEuropean Respiratory Journalpeer reviewers 202229
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance29
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice29
The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands29
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study29
ERJPodcast July 2023: The HISTORIC study28
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?28
Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology28
ERJPodcast December 2023: Year in review28
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma28
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough28
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.28
Ensuring availability of respiratory medicines in times of European drug shortages27
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?27
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?27
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flowFENO?27
Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries26
Genetic associations between Serotonin Receptor 1F (HTR1F) regulatory variation and sleep apnea in non-obese individuals: Insights from GWAS and eQTL analyses26
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury26
All roads lead to COPD… or not?26
Development and validation of a predictive 6-minute walk score in patients with Idiopathic Pulmonary Fibrosis26
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension26
Management of pulmonary hypertension in special conditions25
ERS statement on paediatric long-term noninvasive respiratory support25
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum,et al.Eur Respir25
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children25
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension25
Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis25
Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside25
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia25
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis25
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study25
A randomised trial of prednisoloneversusprednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma25
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-1925
Integrating hot topics and implementation of treatable traits in asthma25
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial24
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection24
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials24
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!24
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis24
The interface in home non-invasive ventilation: is the nasal mask better?24
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults24
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study24
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing24
Heart or lungs? Why not both!24
Drug-induced lung disease: unwanted collateral damage24
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden23
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter,et al.Eur Respir J2021; 58: 200431423
Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis23
Vulnerability to acid reflux of the airway epithelium in severe asthma23
Endothelial cells in pulmonary fibrosis: more than a bystander23
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer23
Latent COPD: a proposed new term in the disease nomenclature23
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis23
Impact of a rare respiratory diseases reference centre set-up on primary ciliary dyskinesia care pathway23
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?23
TB or not TB: does AI have an answer for children?23
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash,et al.Eur Respir J2022; 60: 210181423
Mycobacterium aviumcomplex genomics and transmission in a London hospital23
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9%versus3%versus6% nebulised saline23
MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease23
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease22
Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic22
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis22
Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesis22
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension22
ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer22
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors22
Right heart function during and after pregnancy in women with pulmonary arterial hypertension22
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept22
0.58287119865417